159 related articles for article (PubMed ID: 16897589)
21. Microgranulomatous aspergillosis in a patient with chronic granulomatous disease: cure with voriconazole.
de Sévaux RG; Kullberg BJ; Verweij PE; van de Nes JA; Meis JF; van der Meer JW
Clin Infect Dis; 1998 Apr; 26(4):996-7. PubMed ID: 9564492
[No Abstract] [Full Text] [Related]
22. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.
Hata K; Kimura J; Miki H; Toyosawa T; Moriyama M; Katsu K
Antimicrob Agents Chemother; 1996 Oct; 40(10):2243-7. PubMed ID: 8891122
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis.
Sugar AM; Liu XP
Antimicrob Agents Chemother; 2001 Feb; 45(2):601-4. PubMed ID: 11158762
[TBL] [Abstract][Full Text] [Related]
24. Effects of voriconazole on Cryptococcus neoformans.
van Duin D; Cleare W; Zaragoza O; Casadevall A; Nosanchuk JD
Antimicrob Agents Chemother; 2004 Jun; 48(6):2014-20. PubMed ID: 15155193
[TBL] [Abstract][Full Text] [Related]
25. Amphotericin B is still the drug of choice for invasive aspergillosis.
Agarwal R; Singh N
Am J Respir Crit Care Med; 2006 Jul; 174(1):102; author reply 102-3. PubMed ID: 16793999
[No Abstract] [Full Text] [Related]
26. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.
Aperis G; Mylonakis E
Expert Opin Investig Drugs; 2006 Jun; 15(6):579-602. PubMed ID: 16732713
[TBL] [Abstract][Full Text] [Related]
27. Cryptococcal lung disease in patients without HIV infection.
Sarosi GA
Chest; 1999 Mar; 115(3):610-1. PubMed ID: 10084461
[No Abstract] [Full Text] [Related]
28. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Giannini D; Camiletti V; Fileni B; Giacometti A; Di Francesco LF; Scalise G
J Antimicrob Chemother; 2001 Dec; 48(6):769-73. PubMed ID: 11733459
[TBL] [Abstract][Full Text] [Related]
29. Lack of efficacy of voriconazole therapy in 2 patients with pulmonary fungus balls.
Gutierrez F; Masia M; Ramos JM; Elia M; Rodriguez-Tudela JL; Cuenca-Estrella M
Clin Infect Dis; 2005 Jun; 40(11):1706-7. PubMed ID: 15889381
[No Abstract] [Full Text] [Related]
30. Secondary prophylaxis with voriconazole in a leukemic patient with pulmonary aspergillosis.
Uriz J; de Andoin NG; Calvo C; Landa J; Onate E; Nogues A; Guerrero R
Pediatr Infect Dis J; 2007 Oct; 26(10):971-2. PubMed ID: 17901816
[No Abstract] [Full Text] [Related]
31. Voriconazole: review of a broad spectrum triazole antifungal agent.
Kofla G; Ruhnke M
Expert Opin Pharmacother; 2005 Jun; 6(7):1215-29. PubMed ID: 15957974
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease.
van 't Hek LG; Verweij PE; Weemaes CM; van Dalen R; Yntema JB; Meis JF
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1694-6. PubMed ID: 9603157
[TBL] [Abstract][Full Text] [Related]
33. [Voriconazole - applications and perspectives].
Ruhnke M
Mycoses; 2002; 45 Suppl 3():42-7. PubMed ID: 12690971
[TBL] [Abstract][Full Text] [Related]
34. CRYPTOCOCCOSIS: A bibliographic narrative review on antifungal resistance.
Kakizaki MIT; Melhem MSC
An Acad Bras Cienc; 2023; 95(suppl 1):e20220862. PubMed ID: 37466540
[TBL] [Abstract][Full Text] [Related]
35. [Voriconazole-associated phototoxicity].
Serra Soler G; Delgado Sánchez O; Esteban Marcos E; Martínez-López I; Femenías Sureda M
Farm Hosp; 2006; 30(6):386-7. PubMed ID: 17298198
[No Abstract] [Full Text] [Related]
36. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole.
Denning DW; Griffiths CE
Clin Exp Dermatol; 2001 Nov; 26(8):648-53. PubMed ID: 11722447
[TBL] [Abstract][Full Text] [Related]
37. Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection.
Zaragoza O; Mihu C; Casadevall A; Nosanchuk JD
Antimicrob Agents Chemother; 2005 Oct; 49(10):4358-61. PubMed ID: 16189121
[TBL] [Abstract][Full Text] [Related]
38. In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592).
Yildiran ST; Fothergill AW; Sutton DA; Rinaldi MG
Mycoses; 2002 Nov; 45(9-10):378-83. PubMed ID: 12421285
[TBL] [Abstract][Full Text] [Related]
39. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
[TBL] [Abstract][Full Text] [Related]
40. An update on the use of antifungal agents.
Martinez R
J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
